中毒患者体外膜氧合的应用:叙述性综述与临床建议
本文通过检索Ovid MEDLINE(1946年至2020年10月14日)共筛选330篇文献、纳入156篇,对中毒患者ECMO的使用进行叙述性综述,并由具备ECMO、医学毒理学、重症和急诊医学专长的医师给出建议。回顾性数据显示,因中毒所致难治性休克或心脏骤停接受VA ECMO者死亡率低于非中毒指征接受VA ECMO者;在病情严重度相似并校正分析后,接受ECMO的中毒患者死亡率低于未接受ECMO者,尤以难治性心脏骤停接受VA ECMO(ECPR)者明显。作者建议对难治性心源性休克的中毒患者考虑VA ECMO,对心脏骤停患者在能有效实施ECPR的机构强烈考虑VA ECMO,对ARDS或严重呼吸衰竭按传统ECMO指征考虑VV ECMO,并列出禁忌证。
要点
- 中毒患者接受ECMO呈显著增加趋势;回顾性数据显示VA ECMO用于中毒所致难治性休克或心脏骤停者死亡率低于非中毒指征者。
- 在病情严重度相似并校正分析后,接受ECMO的中毒患者死亡率低于未接受ECMO者,且不限于某一类摄入物。
- 建议对中毒所致难治性心源性休克考虑VA ECMO:液体复苏、血管活性支持及针对性毒理学治疗(如胰高血糖素、静脉脂肪乳、高胰岛素血糖正常治疗等)后仍持续休克伴心肌功能障碍。
- 对心脏骤停的中毒患者,在能有效实施ECPR的机构强烈考虑VA ECMO。
- VV ECMO应按该场景传统ECMO指征用于中毒合并ARDS或严重呼吸衰竭者。
适用人群与场景
- 中毒导致呼吸衰竭、休克、心脏骤停或死亡的患者。
- 难治性心源性休克的中毒患者:液体复苏、血管活性支持及针对性毒理学治疗(如胰高血糖素、静脉脂肪乳、高胰岛素血糖正常治疗等)后仍持续休克伴心肌功能障碍。
- 心脏骤停的中毒患者,仅在能有效实施ECPR的机构中考虑VA ECMO。
- 中毒合并ARDS或严重呼吸衰竭者,按该场景传统ECMO指征考虑VV ECMO。
处置流程与药物剂量
- VA ECMO用于循环支持,VV ECMO用于呼吸支持。
- 中毒所致难治性心源性休克:建议考虑VA ECMO(液体复苏、血管活性支持及针对性毒理学治疗如胰高血糖素、静脉脂肪乳、高胰岛素血糖正常治疗等后仍持续休克伴心肌功能障碍)。
- 中毒所致心脏骤停:在能有效实施ECPR的机构强烈考虑VA ECMO。
- 中毒合并ARDS或严重呼吸衰竭:按该场景传统ECMO指征考虑VV ECMO。
红旗征与不能漏的情况
- 存在低预期生存或恢复的既存合并症为禁忌。
- 相对禁忌因各中心经验而异,常包括:严重脑损伤;高龄;VA ECMO中的未修复主动脉夹层或严重主动脉瓣反流;不可逆器官损伤;全身抗凝禁忌,如严重出血。
研究设计与关键结果
- 文献检索Ovid MEDLINE(1946年至2020年10月14日)识别318条唯一记录,作者另补充12篇手稿,共330篇筛查,最终纳入156篇。
- 中毒患者ECMO使用随时间显著增加。
- 回顾性数据显示,因中毒所致难治性休克或心脏骤停接受VA ECMO者死亡率低于因非中毒指征接受VA ECMO者。
- 在病情严重度相似并校正分析后,接受ECMO的中毒患者死亡率低于未接受ECMO者,且不限于某一类摄入物;尤以难治性心脏骤停接受VA ECMO(ECPR)者明显。
证据类型、等级与局限
- 证据类型:叙述性综述,纳入156篇文献,由具备ECMO、医学毒理学、重症和急诊医学专长的医师给出临床建议。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对中毒所致难治性心源性休克(液体复苏、血管活性支持及针对性毒理学治疗如胰高血糖素、静脉脂肪乳、高胰岛素血糖正常治疗等后仍持续休克伴心肌功能障碍)可考虑VA ECMO。
- 对心脏骤停的中毒患者,在能有效实施ECPR的机构强烈考虑VA ECMO。
- 对中毒合并ARDS或严重呼吸衰竭者,按该场景传统ECMO指征考虑VV ECMO。
- ECMO可为中毒患者提供血流动力学或呼吸支持,同时等待毒物暴露恢复及毒物代谢或清除。
指南或共识出处
- Clin Toxicol (Phila) 发表的叙述性综述《Extracorporeal membrane oxygenation use in poisoning: a narrative review with clinical recommendations》
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Poisoning may lead to respiratory failure, shock, cardiac arrest, or death. Extracorporeal membrane oxygenation (ECMO) may be used to provide circulatory support, termed venoarterial (VA) ECMO; or respiratory support termed venovenous (VV) ECMO. The clinical utility of ECMO in poisoned patients remains unclear and guidelines on its use in this setting are lacking.
OBJECTIVES: To perform a literature search and narrative review on the use of ECMO in poisonings. Additionally, to provide recommendations on the use of ECMO in poisonings from physicians with expertise in ECMO, medical toxicology, critical care, and emergency medicine.
METHODS: A literature search in Ovid MEDLINE from 1946 to October 14, 2020, was performed to identify relevant articles with a strategy utilizing both MeSH terms and adjacency searching that encompassed both extracorporeal life support/ECMO/Membrane Oxygenation concepts and chemically-induced disorders/toxicity/poisoning concepts, which identified 318 unique records. Twelve additional manuscripts were identified by the authors for a total of 330 articles for screening, of which 156 were included for this report.
NARRATIVE LITERATURE REVIEW: The use of ECMO in poisoned patients is significantly increasing over time. Available retrospective data suggest that patients receiving VA ECMO for refractory shock or cardiac arrest due to poisoning have lower mortality as compared to those who receive VA ECMO for non-poisoning-related indications. Poisoned patients treated with ECMO have reduced mortality as compared to those treated without ECMO with similar severity of illness and after adjusted analyses, regardless of the type of ingestion. This is especially evident for poisoned patients with refractory cardiac arrest placed on VA ECMO (termed extracorporeal cardiopulmonary resuscitation [ECPR]).
INDICATIONS: We suggest VA ECMO be considered for poisoned patients with refractory cardiogenic shock (continued shock with myocardial dysfunction despite fluid resuscitation, vasoactive support, and indicated toxicologic therapies such as glucagon, intravenous lipid emulsion, hyperinsulinemia euglycemia therapy, or others), and strongly considered for patients with cardiac arrest in institutions which are structured to deliver effective ECPR. VV ECMO should be considered in poisoned patients with ARDS or severe respiratory failure according to traditional indications for ECMO in this setting.
CONTRAINDICATIONS: Patients with pre-existing comorbidities with low expected survival or recovery. Relative contraindications vary based on each center's experience but often include: severe brain injury; advanced age; unrepaired aortic dissection or severe aortic regurgitation in VA ECMO; irreversible organ injury; contraindication to systemic anticoagulation, such as severe hemorrhage.
CONCLUSIONS: ECMO may provide hemodynamic or respiratory support to poisoned patients while they recover from the toxic exposure and metabolize or eliminate the toxic agent. Available literature suggests a potential benefit for ECMO use in selected poisoned patients with refractory shock, cardiac arrest, or respiratory failure. Future studies may help to further our understanding of the use and complications of ECMO in poisoned patients.
参考来源
- Upchurch C, Blumenberg A, Brodie D, et al. Extracorporeal membrane oxygenation use in poisoning: a narrative review with clinical recommendations. Clin Toxicol (Phila). 2021. PMID: 34396873. doi:10.1080/15563650.2021.1945082
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。